Recent progress and challenges for drug-resistant tuberculosis treatment

Filia Stephanie, Mutiara Saragih, Usman Sumo Friend Tambunan

Research output: Contribution to journalReview articlepeer-review

21 Citations (Scopus)


Control of Mycobacterium tuberculosis infection continues to be an issue, particularly in countries with a high tuberculosis (TB) burden in the tropical and sub-tropical regions. The effort to reduce the catastrophic cost of TB with the WHO’s End TB Strategy in 2035 is still obstructed by the emergence of drug-resistant TB (DR-TB) cases as result of various mutations of the MTB strain. In the approach to combat DR-TB, several potential antitubercular agents were discovered as inhibitors for various existing and novel targets. Host-directed therapy and immunotherapy also gained attention as the drug-susceptibility level of the pathogen can be reduced due to the pathogen’s evolutionary dynamics. This review is focused on the current progress and challenges in DR-TB treatment. We briefly summarized antitubercular compounds that are under development and trials for both DR-TB drug candidates and host-directed therapy. We also highlighted several problems in DR-TB diagnosis, the treatment regimen, and drug discovery that have an impact on treatment adherence and treatment failure.

Original languageEnglish
Article number592
Issue number5
Publication statusPublished - May 2021


  • Drug discovery and development
  • Drug-resistance
  • Host-directed therapy
  • Tuberculosis


Dive into the research topics of 'Recent progress and challenges for drug-resistant tuberculosis treatment'. Together they form a unique fingerprint.

Cite this